Critical Therapeutics Plans Summer Submission Of Zileuton CR
This article was originally published in The Pink Sheet Daily
Executive Summary
An NDA for the extended-release asthma therapy will use Phase III studies conducted by zileuton CR developer Abbott.
You may also be interested in...
Critical Therapeutics Submits Zileuton CR
Critical Therapeutics' controlled-release zileuton could cut the current dosing regimen for Zyflo by half, the firm said July 31
GAO Urges Congress To Place EPO, Other Dialysis Services In Bundled Rates
The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.